Zhanshi consulting 2019 Asia Pacific pharmaceutical intellectual property leaders summit successfully concluded in Beijing

The 2019 Asia Pacific pharmaceutical intellectual property leaders summit was officially held in Beijing on November 14 This summit was hosted by Shanghai Zhanshi Business Consulting Co., Ltd and brought together more than 260 industry experts from regulatory agencies, industry associations, well-known pharmaceutical companies, biotechnology companies, law firms, intellectual property agency companies, IP solution suppliers, etc On the first day of the conference, Professor He Min, intellectual property School of East China University of political science and law, and lawyer Mu Ying, partner of global law firm, presided over the conference in the last afternoon, opening the wonderful sharing prologue with the themes of "regulatory reform, interpretation of pharmaceutical intellectual property laws and policies in the new situation" and "pharmaceutical R & D innovation and intellectual property protection - Global Vision" First day sharing Speaker: On the second day of the conference, Xing Weihong, head of life science department of Panshi intellectual property law firm, and He Jing, a lawyer from Zhide law firm, presided over the conference in the afternoon Many industry leaders focused on the issues of invalidity, infringement, litigation case analysis, injunctive relief after drug patents were included in drug standards, 2019 global innovation index analysis (Biomedical In the new situation, the opportunities and challenges faced by generic pharmaceutical enterprises and other hot topics delivered a wonderful speech Next day's guest speaker: so far, the two-day 2019 Asia Pacific pharmaceutical intellectual property leaders summit ended successfully Zhanshi consulting hopes to keep close cooperation with senior experts, excellent enterprises and institutions in the industry, provide cutting-edge information in the industry, explore the development trend of the industry, promote business exchanges in the industry, and jointly promote better, faster and healthier development in the field of pharmaceutical intellectual property and related industries Penicillin statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.